John T. Callaghan

4.7k total citations · 1 hit paper
42 papers, 2.1k citations indexed

About

John T. Callaghan is a scholar working on Pharmacology, Pharmacology and Molecular Biology. According to data from OpenAlex, John T. Callaghan has authored 42 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 12 papers in Pharmacology and 9 papers in Molecular Biology. Recurrent topics in John T. Callaghan's work include Pharmacogenetics and Drug Metabolism (15 papers), Pharmaceutical studies and practices (7 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). John T. Callaghan is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Pharmaceutical studies and practices (7 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). John T. Callaghan collaborates with scholars based in United States, Australia and Ireland. John T. Callaghan's co-authors include Richard F. Bergstrom, Teri E. Klein, Charles M. Beasley, Louis R. Ptak, Andrea Gaedigk, Todd C. Skaar, Danny D. Shen, Henry M. Dunnenberger, Kristine R. Crews and Kelly E. Caudle and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Life Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

John T. Callaghan

41 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

2014 453 citations Kristine R. Crews, Andrea Gaedigk et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John T. Callaghan United States	17	879	485	423	385	328	42	2.1k
E D Kharasch United States	14	1.4k 1.5×	569 1.2×	343 0.8×	211 0.5×	286 0.9×	25	2.1k
JS Leeder United States	10	1.3k 1.5×	904 1.9×	386 0.9×	290 0.8×	281 0.9×	10	2.3k
Juan Antonio Carrillo Spain	24	831 0.9×	247 0.5×	478 1.1×	376 1.0×	383 1.2×	54	2.0k
Su Duan United States	26	1.6k 1.8×	531 1.1×	458 1.1×	243 0.6×	534 1.6×	43	2.9k
Séverine Crettol Switzerland	18	586 0.7×	454 0.9×	186 0.4×	253 0.7×	289 0.9×	40	1.5k
Caroline Samer Switzerland	28	832 0.9×	440 0.9×	283 0.7×	139 0.4×	295 0.9×	107	2.5k
S. Schenker United States	36	1.0k 1.1×	863 1.8×	392 0.9×	327 0.8×	556 1.7×	107	3.7k
Jan van der Weide Netherlands	27	1.6k 1.8×	721 1.5×	415 1.0×	563 1.5×	553 1.7×	47	2.8k
GT Tucker United Kingdom	27	1.4k 1.6×	399 0.8×	675 1.6×	304 0.8×	648 2.0×	88	3.3k
Einosuke Tanaka Japan	25	1.0k 1.2×	316 0.7×	319 0.8×	169 0.4×	309 0.9×	139	2.3k

Countries citing papers authored by John T. Callaghan

Since Specialization

Citations

This map shows the geographic impact of John T. Callaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John T. Callaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John T. Callaghan more than expected).

Fields of papers citing papers by John T. Callaghan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John T. Callaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John T. Callaghan. The network helps show where John T. Callaghan may publish in the future.

Co-authorship network of co-authors of John T. Callaghan

This figure shows the co-authorship network connecting the top 25 collaborators of John T. Callaghan. A scholar is included among the top collaborators of John T. Callaghan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John T. Callaghan. John T. Callaghan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Yuling, Ayşe Gelal, Chisook Moon, et al.. (2025). Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants. Drug Metabolism and Disposition. 53(10). 100156–100156.

Ly, Reynold C., Santosh Philips, Milan Radovich, et al.. (2022). Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. JCO Precision Oncology. 6(6). e2100312–e2100312. 11 indexed citations

Ly, Reynold C., Santosh Philips, Marc B. Rosenman, et al.. (2022). Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer. Frontiers in Cardiovascular Medicine. 9. 1 indexed citations

Vassy, Jason L., Annjanette Stone, John T. Callaghan, et al.. (2018). Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. Genetics in Medicine. 21(2). 382–390. 10 indexed citations

Desta, Zeruesenay, Ingrid F. Metzger, Jessica Bo Li Lu, et al.. (2016). Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 60(11). 6813–6822. 13 indexed citations

Metzger, Ingrid F., Troy C. Quigg, John T. Callaghan, et al.. (2014). Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers. Current Therapeutic Research. 76. 64–69. 12 indexed citations

Crews, Kristine R., Andrea Gaedigk, Henry M. Dunnenberger, et al.. (2011). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. Clinical Pharmacology & Therapeutics. 91(2). 321–326. 278 indexed citations

Derby, Michael A., Celedon Gonzales, Jill Chappell, et al.. (2005). QT interval analyses from a placebo and positive controlled study evaluating the electrophysiological effects of duloxetine at supratherapeutic doses. Clinical Pharmacology & Therapeutics. 77(2). P12–P12. 2 indexed citations

Callaghan, John T., et al.. (2002). The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. British Journal of Clinical Pharmacology. 53(1). 67–74. 54 indexed citations

10.

Callaghan, John T., Richard F. Bergstrom, Louis R. Ptak, & Charles M. Beasley. (1999). Olanzapine. Clinical Pharmacokinetics. 37(3). 177–193. 429 indexed citations

11.

Macias, William L., et al.. (1998). Lack of Effect of Olanzapine on the Pharmacokinetics of a Single Aminophylline Dose in Healthy Men. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(6). 1237–1248. 11 indexed citations

12.

Foster, Richard S., et al.. (1990). Role of serum prolactin determination in evaluation of impotent patient. Urology. 36(6). 499–501. 17 indexed citations

13.

Schneck, Dennis W., John T. Callaghan, Richard F. Bergstrom, Boyd D. Obermeyer, & Walter Offen. (1990). Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion. Clinical Pharmacology & Therapeutics. 47(4). 499–503. 7 indexed citations

14.

Obermeyer, Boyd D., Richard F. Bergstrom, John T. Callaghan, et al.. (1990). Secretion of nizatidine into human breast milk after single and multiple doses. Clinical Pharmacology & Therapeutics. 47(6). 724–730. 11 indexed citations

15.

Callaghan, John T., et al.. (1990). Disposition in humans of racemic picenadol, an opioid analgesic.. Drug Metabolism and Disposition. 18(6). 968–973. 2 indexed citations

16.

Aronoff, George R., Richard F. Bergstrom, Ronald J. Bopp, Rebecca Sloan, & John T. Callaghan. (1988). Nizatidine disposition in subjects with normal and impaired renal function. Clinical Pharmacology & Therapeutics. 43(6). 688–695. 18 indexed citations

17.

Callaghan, John T., et al.. (1988). Double-Blind Comparator Trials with Pinacidil, a Potassium Channel Opener. Drugs. 36(Supplement 7). 77–82. 11 indexed citations

18.

Callaghan, John T., R. F. Bergstrom, Alan Rubin, et al.. (1987). A Pharmacokinetic Profile of Nizatidine in Man. Scandinavian Journal of Gastroenterology. 22(sup136). 9–17. 40 indexed citations

19.

Callaghan, John T., Alan Rubin, Mary Pat Knadler, & Richard F. Bergstrom. (1987). Nizatidine, an H₂‐Receptor Antagonist: Disposition and Safety in the Elderly. The Journal of Clinical Pharmacology. 27(8). 618–624. 12 indexed citations

20.

Callaghan, John T., et al.. (1983). Effect of cholestyramine and colestipol on the absorption of phenytoin. European Journal of Clinical Pharmacology. 24(5). 675–678. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact